BRPI0923403B1 - Composições para administração de fármaco - Google Patents

Composições para administração de fármaco Download PDF

Info

Publication number
BRPI0923403B1
BRPI0923403B1 BRPI0923403-9A BRPI0923403A BRPI0923403B1 BR PI0923403 B1 BRPI0923403 B1 BR PI0923403B1 BR PI0923403 A BRPI0923403 A BR PI0923403A BR PI0923403 B1 BRPI0923403 B1 BR PI0923403B1
Authority
BR
Brazil
Prior art keywords
drug
composition
alkyl
maltoside
composition according
Prior art date
Application number
BRPI0923403-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Edward T. Maggio
Original Assignee
Aegis Therapeutics, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aegis Therapeutics, Llc filed Critical Aegis Therapeutics, Llc
Publication of BRPI0923403A2 publication Critical patent/BRPI0923403A2/pt
Publication of BRPI0923403B1 publication Critical patent/BRPI0923403B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0923403-9A 2008-12-22 2009-12-22 Composições para administração de fármaco BRPI0923403B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/341,696 US8268791B2 (en) 2004-08-25 2008-12-22 Alkylglycoside compositions for drug administration
US12/341,696 2008-12-22
PCT/US2009/069326 WO2010075465A1 (en) 2008-12-22 2009-12-22 Compositions for drug administration

Publications (2)

Publication Number Publication Date
BRPI0923403A2 BRPI0923403A2 (pt) 2020-08-11
BRPI0923403B1 true BRPI0923403B1 (pt) 2022-02-08

Family

ID=42288137

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923403-9A BRPI0923403B1 (pt) 2008-12-22 2009-12-22 Composições para administração de fármaco

Country Status (14)

Country Link
US (1) US8268791B2 (OSRAM)
EP (1) EP2381773B1 (OSRAM)
JP (2) JP5752048B2 (OSRAM)
KR (1) KR101719008B1 (OSRAM)
CN (1) CN102325450B (OSRAM)
AU (1) AU2009329952B2 (OSRAM)
BR (1) BRPI0923403B1 (OSRAM)
CA (1) CA2748268C (OSRAM)
DK (1) DK2381773T3 (OSRAM)
ES (1) ES2667248T3 (OSRAM)
MX (1) MX356271B (OSRAM)
NZ (1) NZ593782A (OSRAM)
RU (1) RU2554814C2 (OSRAM)
WO (1) WO2010075465A1 (OSRAM)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
ATE481963T1 (de) 2006-05-30 2010-10-15 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
PL2124556T3 (pl) 2006-10-09 2015-02-27 Charleston Laboratories Inc Kompozycje farmaceutyczne
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
US20080279784A1 (en) * 2007-05-07 2008-11-13 Questcor Pharmaceuticals, Inc. Nasal administration of benzodiazepines
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
CA3066426A1 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
EP2271347B1 (en) 2008-03-28 2016-05-11 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US9775819B2 (en) * 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
CN102933198B (zh) * 2009-09-25 2015-10-07 雷迪博士实验室有限公司 包含曲普坦化合物的制剂
KR101646079B1 (ko) * 2009-09-25 2016-08-12 닥터 레디스 레보러터리즈 리미티드 트립탄 화합물을 포함하는 제제
BR112012007087A2 (pt) * 2009-09-25 2020-08-11 Dr. Reddy's Laboratoires Limited composições farmacêuticas compreendendo compostos triptano e uso das mesmas para a preparação de um medicamento para tratar condições associadas à dor cefálica
KR102093612B1 (ko) * 2009-09-28 2020-03-26 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
WO2011075611A1 (en) * 2009-12-18 2011-06-23 Aegis Therapeutics, Llc Compositions and methods for non-invasive treatment of chronic complication of diabetes
US20120035103A1 (en) * 2010-01-29 2012-02-09 Pillion Dennis J Method for administration of insulin and pharmaceutical composition thereof
WO2013071396A1 (en) * 2011-11-18 2013-05-23 Université de Montréal Oral leptin formulations and uses thereof
US20150132344A1 (en) * 2010-11-18 2015-05-14 Universite De Montreal Oral Leptin Formulations and Uses Thereof
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP3415139B8 (en) 2011-06-14 2022-05-18 Neurelis, Inc. Administration of benzodiazepine
CA3098386C (en) * 2012-07-12 2022-11-29 Mannkind Corporation Dry powder drug delivery systems and methods
WO2015032981A1 (en) * 2013-09-09 2015-03-12 Lek Pharmaceuticals D.D. Erythropoietin conjugates having oral bioavailability
US10188736B2 (en) 2013-09-30 2019-01-29 Enza Biotech Ab Surfactant composition
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
SG11201705640PA (en) * 2015-02-17 2017-08-30 Lilly Co Eli Nasal powder formulation for treatment of hypoglycemia
KR102650751B1 (ko) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
WO2017004501A1 (en) 2015-07-02 2017-01-05 Civitas Therapeutics, Inc. Triptan powders for pulmonary delivery
EP3368159A1 (en) * 2015-10-28 2018-09-05 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions for rizatriptan
CN108135959B (zh) 2015-10-30 2021-12-31 帝人制药株式会社 鼻粘膜给药用药物组合物
CA3055170A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
CA3024479A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US20190209464A1 (en) * 2016-06-24 2019-07-11 Opiant Pharmaceuticals, Inc. Compositions, devices and methods for the treatment of alcohol use disorder
WO2018093666A1 (en) * 2016-11-18 2018-05-24 Opiant Pharmaceuticals, Inc. Compositions and methods for the treatment of opioid overdose
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
CA3052757A1 (en) * 2017-02-09 2018-08-16 Sekisui Chemical Co., Ltd. Core-shell structure, preparation, medicine for external application, tape agent and cosmetic product
WO2019157099A1 (en) 2018-02-06 2019-08-15 Aegis Therapeutics, Llc Intranasal epinephrine formulations and methods for the treatment of disease
WO2020049523A1 (en) 2018-09-07 2020-03-12 Upsher-Smith Laboratories, Llc Methods of treating migraine
SG11202106531VA (en) * 2018-12-20 2021-07-29 Aegis Therapeutics Llc Compositions, devices, and methods for the treatment of overdose and reward-based disorders
MY198967A (en) * 2019-02-06 2023-10-05 Axsome Therapeutics Inc Pharmaceutical compositions comprising meloxicam
CN114007617A (zh) * 2019-05-31 2022-02-01 葡瑞慕生物技术有限公司 用于经黏膜给药药物活性成分的单位剂型
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
MX2023005846A (es) * 2020-11-19 2023-06-02 Pfizer Ireland Pharmaceuticals Composiciones para la administracion mejorada de los inhibidores de cgrp.
CN116456981A (zh) * 2020-11-19 2023-07-18 辉瑞爱尔兰制药公司 用于改善的grp抑制剂递送的组合物
IL310566A (en) 2021-08-04 2024-03-01 Indivior Inc Preparations and methods for the treatment of opioid overdose
WO2024209050A1 (en) 2023-04-05 2024-10-10 Antag Therapeutics Aps Gip activity modulators and orthostatic intolerance
CN118924882A (zh) * 2023-05-10 2024-11-12 上海仁会生物制药股份有限公司 药物组合物及其用途、提高药物组合物贮存稳定性的方法
US12005077B1 (en) * 2023-09-28 2024-06-11 Terry Earl Brady Broad-spectrum antimicrobial, biocompatible and preservative-free functionalized fullerenes ophthalmic solution with reactive oxygen species scavenging and advanced targeting, penetration, and hydration

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US411210A (en) 1889-09-17 Water-wheel
US3219656A (en) 1963-08-12 1965-11-23 Rohm & Haas Alkylpolyalkoxyalkyl glucosides and process of preparation therefor
US3547828A (en) * 1968-09-03 1970-12-15 Rohm & Haas Alkyl oligosaccharides and their mixtures with alkyl glucosides and alkanols
US3839318A (en) 1970-09-27 1974-10-01 Rohm & Haas Process for preparation of alkyl glucosides and alkyl oligosaccharides
GB1355998A (en) * 1970-09-30 1974-06-12 Unilever Ltd Builders for detergent compositions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4036228A (en) 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4130709A (en) * 1977-12-08 1978-12-19 Eli Lilly And Company Pleuromutilin glycoside derivatives
JPS57128634A (en) * 1981-02-03 1982-08-10 Eisai Co Ltd Elastase-containing compound increasing absorption
US4440675A (en) * 1981-08-18 1984-04-03 Meloy Laboratories, Inc. Human immune interferon
AT382381B (de) 1984-10-02 1987-02-25 Oesterr Zuckerfab Evidenz Verfahren zur herstellung neuer grenzfl|chenaktiver kohlenhydrat-derivate
DE3444958A1 (de) * 1984-12-10 1986-06-12 Henkel KGaA, 4000 Düsseldorf Verwendung von alkylglykosiden als potenzierungsmittel in antiseptischen mitteln sowie desinfektions- und reinigungsmittel mit verstaerkter bakterizider wirkung
DK17685D0 (da) * 1985-01-14 1985-01-14 Hans Goeran Magnusson Glycosidderivater
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US5550220A (en) * 1987-05-13 1996-08-27 Curtice-Burns, Inc. Alkyl glycoside fatty acid polyester fat substitute food compositions and process to produce the same
US4938931A (en) 1987-05-26 1990-07-03 Hoechst Celanese Corporation Microporous membrane trickle bed reactor
US4921838A (en) * 1987-06-16 1990-05-01 Trustees Of Boston University Angiogenic and blood perfusion inducing properties of amphiphilic compounds
EP0396777A4 (en) 1988-11-14 1991-03-13 Otsuka Pharmaceutical Co., Ltd. Interferon preparation for nasal administration
US5705363A (en) * 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5182258A (en) * 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
US5122187A (en) * 1989-06-22 1992-06-16 Xerox Corporation Hot melt ink compositions
US5198420A (en) * 1989-10-02 1993-03-30 The General Hospital Corporation Use of mullerian inhibiting substance and its agonists and antagonists in the treatment of respiratory distress syndrome
US5369095A (en) * 1990-02-14 1994-11-29 Alcon Laboratories, Inc. Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
AU638146B2 (en) * 1990-06-27 1993-06-17 Dainippon Ink And Chemicals Inc. Alkylated oligosaccharides and acetyl derivatives of the same
US5288707A (en) 1990-08-13 1994-02-22 Sandoz Ltd. Borolysine peptidomimetics
EP0513813B1 (en) * 1991-05-16 1996-10-09 Kao Corporation Alkyl glycoside aqueous solution stable to microbial activity
US5552534A (en) 1991-08-22 1996-09-03 The Trustees Of The University Of Pennsylvania Non-Peptide peptidomimetics
US5317010A (en) * 1991-10-10 1994-05-31 Peter K. T. Pang Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment
US5236707A (en) * 1991-11-08 1993-08-17 Dallas Biotherapeutics, Inc. Stabilization of human interferon
US5550251A (en) 1991-12-12 1996-08-27 The Trustees Of The University Of Pennsylvania Alicyclic peptidomimetics
US5308531A (en) * 1992-08-31 1994-05-03 Henkel Corporation Pine-oil containing hard surface cleaning composition
WO1994005262A1 (en) 1992-09-10 1994-03-17 F.H. Faulding & Co. Limited Sustained release matrix composition
ES2179831T3 (es) * 1992-09-29 2003-02-01 Inhale Therapeutic Syst Liberacion en los pulmones de fragmentos activos de hormona paratiroidiana.
WO1994020116A1 (en) * 1993-03-10 1994-09-15 University Of Alabama Research Foundation Artificial primers for glycogen synthesis
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
US6794357B1 (en) * 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5510264A (en) * 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
CA2174324A1 (en) * 1993-10-21 1995-04-27 Katsuya Mukae Pernasal composition and pernasal preparation containing the same
US5576014A (en) 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5955425A (en) * 1996-08-02 1999-09-21 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
CA2126299C (en) * 1994-06-20 2000-12-12 Gordon E. Willick Parathyroid hormone analogues for the treatment of osteoporosis
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
SE9404468D0 (sv) * 1994-12-22 1994-12-22 Astra Ab Powder formulations
SK81197A3 (en) * 1994-12-22 1997-11-05 Astra Ab Aerosol drug formulations, method for production thereof and its use
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US20030118594A1 (en) * 1995-06-07 2003-06-26 Bishwajit Nag Stable formulations of mhc-peptide complexes
US6852690B1 (en) * 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US6254854B1 (en) * 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US20050004049A1 (en) 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6245760B1 (en) * 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
AU731909B2 (en) * 1997-07-01 2001-04-05 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
ITMI981528A1 (it) 1998-07-03 2000-01-03 Recordati Ind Chimica E Farma Formulazioni topiche di aciclovir
FR2781152B1 (fr) 1998-07-20 2001-07-06 Permatec Tech Ag Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation
US20030087820A1 (en) * 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
US6495498B2 (en) * 1999-05-27 2002-12-17 Johnson & Johnson Consumer Companies, Inc. Detergent compositions with enhanced depositing, conditioning and softness capabilities
US7144574B2 (en) * 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US6316410B1 (en) * 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
IL150109A0 (en) * 1999-12-09 2002-12-01 Chiron Corp Method for administering a cytokine to the central nervous system and the lymphatic system
US20030118547A1 (en) * 2000-01-27 2003-06-26 Vandenberg Grant William Composition for intestinal delivery
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US20040147473A1 (en) * 2000-11-10 2004-07-29 Warrell Raymond P. Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
WO2002043750A2 (en) * 2000-12-01 2002-06-06 Battelle Memorial Institute Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations
US6551578B2 (en) * 2001-02-15 2003-04-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US7316819B2 (en) * 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
CA2451643C (en) 2001-06-21 2012-11-13 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
ES2334268T3 (es) * 2002-06-07 2010-03-08 Waratah Pharmaceuticals, Inc. Procedimientos y composiciones para el tratamiento de la diabetes.
US20060106227A1 (en) * 2002-06-13 2006-05-18 Dr Reddy's Laboratories Limited 3-'2-(Dimethylamino) ethyl!-n-methyl-1h-indole-5-methanesulfonamide and the succinate thereof
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
CA2498931A1 (en) * 2002-09-16 2004-03-25 Wyeth Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same
GB0226076D0 (en) 2002-11-08 2002-12-18 Rp Scherer Technologies Inc Improved formulations containing substituted imidazole derivatives
US7166575B2 (en) * 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US20040248846A1 (en) * 2003-04-22 2004-12-09 Nastech Pharmaceutical Company Inc. Intranasal administration of triptans
US20040258663A1 (en) * 2003-05-08 2004-12-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon alpha
ES2425221T3 (es) * 2003-05-30 2013-10-14 Amylin Pharmaceuticals, Llc Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
EP1656102A2 (en) * 2003-08-21 2006-05-17 Transoral Pharmaceuticals, Inc. Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof
EP1550669B1 (en) * 2003-12-15 2008-08-06 M-Phasys GmbH Refolded membrane protein in monodisperse form
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
DE102004017934A1 (de) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
CN101151048A (zh) * 2004-05-10 2008-03-26 纳斯泰克制药公司 增强甲状旁腺激素粘膜递送的组合物和方法
EP2457580A1 (en) 2004-08-25 2012-05-30 The UAB Research Foundation Absorption enhancers for drug administration
US20060046969A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Antibacterial compositions for drug administration
US20060046962A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US9114069B2 (en) * 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
JP5175103B2 (ja) 2004-11-12 2013-04-03 ノヴォ ノルディスク アー／エス 安定なペプチド製剤
TWI372629B (en) * 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
US7390788B2 (en) * 2005-06-23 2008-06-24 Pert Candace B Peptide pharmaceutical compositions
US20090326193A1 (en) * 2006-06-23 2009-12-31 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) * 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) * 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7425542B2 (en) * 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
AR068500A1 (es) * 2007-09-21 2009-11-18 Saint Gobain Abrasives Inc Metilol melamina para productos abrasivos

Also Published As

Publication number Publication date
DK2381773T3 (en) 2018-05-28
MX2011006790A (es) 2011-09-27
MX356271B (es) 2018-05-21
JP5752048B2 (ja) 2015-07-22
KR20110099049A (ko) 2011-09-05
RU2554814C2 (ru) 2015-06-27
HK1164059A1 (en) 2012-09-21
BRPI0923403A2 (pt) 2020-08-11
NZ593782A (en) 2012-11-30
EP2381773B1 (en) 2018-02-14
RU2011130526A (ru) 2013-01-27
KR101719008B1 (ko) 2017-03-22
CA2748268C (en) 2018-05-15
AU2009329952A1 (en) 2011-07-21
CN102325450B (zh) 2015-06-17
US20090163447A1 (en) 2009-06-25
EP2381773A1 (en) 2011-11-02
JP2015108008A (ja) 2015-06-11
CA2748268A1 (en) 2010-07-01
CN102325450A (zh) 2012-01-18
EP2381773A4 (en) 2012-12-12
AU2009329952B2 (en) 2014-01-09
US8268791B2 (en) 2012-09-18
ES2667248T3 (es) 2018-05-10
JP2012513412A (ja) 2012-06-14
WO2010075465A1 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
EP2381773B1 (en) Compositions for drug administration
US9283280B2 (en) Compositions for drug administration
US10265402B2 (en) Absorption enhancers for drug administration
US11173209B2 (en) Compositions for drug administration
US20110257096A1 (en) Compositions for drug administration
US20090047347A1 (en) Compositions for Drug Administration
US8642564B2 (en) Compositions for drug administration
US20120021980A1 (en) Compositions for drug administration
HK1164059B (en) Compositions for drug administration
HK1185814A (en) Compositions for drug administration

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 43/38 , A61K 31/40

Ipc: A61K 31/40 (2006.01), A61K 31/4439 (2006.01), A61K

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/12/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.